EP2111415A2 - Monoclonal agonistic anti-ctla-4 antibodies - Google Patents
Monoclonal agonistic anti-ctla-4 antibodiesInfo
- Publication number
- EP2111415A2 EP2111415A2 EP05826461A EP05826461A EP2111415A2 EP 2111415 A2 EP2111415 A2 EP 2111415A2 EP 05826461 A EP05826461 A EP 05826461A EP 05826461 A EP05826461 A EP 05826461A EP 2111415 A2 EP2111415 A2 EP 2111415A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- ctla
- antibody
- monoclonal antibody
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001270 agonistic effect Effects 0.000 title claims abstract description 10
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 96
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract description 94
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000024691 pancreas disease Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 32
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 28
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 28
- 238000009739 binding Methods 0.000 description 24
- 230000004913 activation Effects 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 17
- 108020003175 receptors Proteins 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 11
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 10
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 108700010039 chimeric receptor Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000004073 interleukin-2 production Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical class 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 230000002483 superagonistic effect Effects 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 102000043321 human CTLA4 Human genes 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004940 costimulation Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007896 negative regulation of T cell activation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000859077 Mus musculus Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-O cyclohexylammonium Chemical compound [NH3+]C1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-O 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Definitions
- the invention relates to an antibody which is specific for CTLA-4, a pharmaceutical composition containing such an antibody, nucleic acids encoding such antibodies, vectors containing such antibodies, cells transfected with such vectors, uses of such antibodies, methods for producing such antibodies, and methods for Preparation of a pharmaceutical composition containing such antibodies.
- T lymphocytes are the main agents of a highly efficient immune response that protects the human body against invading pathogens such as bacteria and viruses. They regulate the molecular interaction between different cellular components of the immune system such as dendritic cells, B cells, macrophages or other T cells and perform important effector functions such as the destruction of virus-infected cells or tumor cells themselves. As a result, they occupy a key position in the initiation and coordination of an immune response.
- TCRs T cell antigen receptors
- HLA major histocompatibility complex
- CD receptors control the extent and quality of the response of the T cell.
- a signal combination of TCR and at least one other CD receptor is required for the complete activation of T cells, which is characterized in particular by proliferation and cytokine production. This process is called "costimulation.”
- costimulation The most important costimulatory CD molecule on quiescent human T cells is the CD28 molecule.
- T cells Activation of T cells are effectively shut down. This task is accomplished through the interaction of a number of immunological control mechanisms. A particularly important role is played by inhibitory cell surface receptors such as the "Cytotoxic T-Lymphocyte Antigen-4" (CTLA-4) molecule, which will be explained in detail later.
- CTL-4 Cytotoxic T-Lymphocyte Antigen-4"
- Organ transplants d. H . in transplantation among non-HLA-identical individuals, activation of the T cells of the recipient is undesirable because activation of T cells by recognition of allo-antigens is the major cause of a chronic rejection reaction.
- CTLA-4 ' (CD152) is a member of the immunoglobulin superfamily and structurally the closest relative of CD28 (Lenschow DJ, Walunas TL, Bluestone JA, CD28 / B7 system of T cell costimulation., Annu Rev Immunol, 1996. 14: 233- 58).
- CD28 the physiological function of CTLA-4 is not the promotion, but the inhibition of T-cell activation.
- CTLA-4 is very weak on quiescent T cells and strongly expressed on the cell surface of activated and regulatory T cells.
- CTLA-4 The binding of CTLA-4 to its natural ligands B7-1 (CD80) and B7-2 (CD86), which are expressed by antigen-presenting cells (APC), leads to a shutdown of T cell proliferation and suppression of the Cytokine expression (Egen JG, Kuhns MS, Allison JP, CTLA-4: new entry into biological function and use in tumor immunotherapy, Nat Immunol, 2002. 3 (7): 611-8).
- CTLA-4 The inhibitory function of CTLA-4 on the T cell surface was first determined using immobilized monoclonal antibodies specific for mouse CTLA-4 molecule (Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA _ ⁇ _ CTLA-4 can function as a negative regulator of cell activation, Immunity, 1994.1 (5): 405-13) and man (Blair PJ, Riley JL, Levine BL, Lee KP, Craighead N, Francomano T, Perfetto SJ, Gray GS, Carreno BM, June CH, CTLA-4 ligation dellvers a unique signal to resting human
- CTLA-4 blockade enhances the activation of T cells in vivo. Accordingly, blocking, ie antagonistic, anti-CTLA-4 antibodies potentiated an anti-tumor response (Chambers CA, Allison JP, Co-stimulation in cell responses, Curr Opin Immunol, 1997. 9 (3): 396-404), to lead but also autoimmunity (Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D, Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes J Exp Med, 1998. 187 (3)): 427-32). These findings, which were initially obtained in the mouse system, could be confirmed in humans in the first clinical trials.
- a polymorphism in the CTLA-4 gene that results in decreased expression and functionality of the CTLA-4 protein correlates with an increased likelihood of human involvement in the autoimmune diseases rheumatoid arthritis (Seidl C, Donner H, Fischer B, Usadel KH, Seifried E , Coldwater JP, Badenhoop K, CTLA4 codon 11 dimorphism in patients with rheumatoid arthritis Tissue Antigens, 1998.
- agonist anti-CTLA-4 antibodies should be immunosuppressive.
- this has so far only been convincingly demonstrated for artificially immobilized antibodies.
- the genetically engineered transmembrane expression of an anti-CTLA-4 "single chain" antibody on artificial APC reduced TCR mediated proliferation and interleukin-2 secretion of T cells (Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, Mammin SM, Fallarino F, Collins M, Segal DM, Gaj ewski TF, Wreath DM, Bluestone JA, Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152) .J Immunol, 2000.
- CTLA-4 antibody specific for the C 'D loop of the extracellular domain of CTLA-4 (Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL Greenfield E, Barber M, Restivo VA Jr, X Ke, Gray GS, Nadler LM, CTLA4 mediates antigen-specific apoptosis of human T cells, Proc Natl Acad Sci USA, 1995. 92 (3): 811-5).
- Targeted and well-tolerated inactivation of T cells by stimulating the inhibitory function of CTLA-4 would be desirable in the above-mentioned indications.
- the invention is therefore based on the technical problem of providing substances and pharmaceutical compositions capable of stimulating the inhibitory function of CTLA-4.
- the invention teaches an isolated monoclonal antibody specific and agonistic to CTLA-4, the heavy chain of the antibody containing a sequence selected from the group consisting of (Seq. ID): "22 , 23, 24, 25, 26, 27, 28, 29, 30, and 32 ".
- the light chain of the antibody may contain a sequence selected from the group consisting of (Seq. ID):" 33, 34 , 35, 36, 37, and 38 ".
- An antibody according to the invention with a heavy chain containing a sequence according to Seq. ID 27, 28, or 29, preferably containing or consisting of Sequence according to Seq. ID 30 or 32, and with a light chain containing a sequence according to Seq. ID 36 or 37, preferably containing or consisting of a sequence according to Seq. ID 38.
- a specific antibody having the above basic structure are the following antibodies TGN2122. H and TGN2422. H .
- the invention teaches an isolated monoclonal antibody which is specific and agonistic to CTLA-4, the heavy chain of the antibody containing a sequence selected from the group consisting of (Seq. ID): "43, 44,” 45, 46, 47, 48, 49, 50, 51, and 53 ".
- the light chain of the antibody may contain a sequence selected from the group consisting of (Seq. ID):" 54, 55, 56, 57, 58, and 59 ⁇ .
- an antibody according to the invention with a heavy chain containing a sequence according to Seq. ID 48, 49, or 50, preferably containing or consisting of the sequence according to Seq. ID 51 or 53, as well as with a light chain containing a sequence according to Seq. ID 57 or 58, preferably containing or consisting of a sequence according to Seq. ID 59.
- a specific antibody having the above basic structure are the following antibodies TGN2122. C and TGN2422. C.
- the antibodies mentioned above are humanized antibodies. Since it is already one humanized antibody, as described below for other variants of antibodies according to the invention is not required.
- the antibody may or may not bind to the C '' D loop of CTLA-4. Rather, it may also be an antibody that does not bind to this loop.
- the invention teaches an isolated monoclonal antibody which is specific and agonistic to CTLA-4, wherein the antibody does not bind to a CTLA-4 partial sequence according to SEQ. ID 1 binds.
- the sequence according to SEQ. ID 1 is the C 'D loop of the CTLA-4.
- an antibody of the invention binds to other regions of the CTLA-4 molecule than the C "D loop.
- the invention is based on the finding that an agonistic stimulation of CTLA-4, i. e. inducing the inhibitory activity of CTLA-4 in vivo, constitutes a useful therapeutic concept for autoimmune diseases or transplantation, and provides suitable drugs in the form of the antibodies or fragments thereof.
- an antibody according to the invention contains at least one of the sequences according to SEQ. ID 2 to SEQ. ID 7 or SEQ. ID 8 to SEQ. -ID 13. These sequences are the CDRs of the heavy and light chain variable regions, with additional reference to Table 2.
- an antibody according to the invention is humanized. This can be done in a customary manner, for example by using a human CTLA-4-specific monoclonal mouse antibody is chimaerized in such a way that the constant regions are exchanged for human or human-compatible constant regions. It is essential that preferably all CDRs according to Table 2 are maintained and indeed in their spatial arrangement to each other.
- monoclonal antibodies can be used which at least one, preferably all, sequences according to SEQ. ID 2 to SEQ. ID 7 or SEQ. ID 8 to SEQ. ID 13, for example one of the sequences according to SEQ. ID 14 to 17, included.
- antibodies according to the invention can also be one of the sequences according to SEQ. ID 18 to 21 included.
- Suitable embodiments of antibodies which form a basis for humanization are the antibodies 4.8H10H5 and 4.3F6B5 described in detail below. A preparation of humanized antibodies from this is possible in a conventional manner, for example by genetic engineering humanization strategies.
- antibody encompasses, in addition to the structures explicitly disclosed, also functionally corresponding antibodies which have been modified, for example, by chimerization, humanization or de-immunization (excision of T-cell epitopes from the human antibody which trigger undesired immune reactions) and specific antibodies Fragments of the light and / or heavy chain variable region underlying antibody of the above type.
- chimerization humanization or de-immunization (excision of T-cell epitopes from the human antibody which trigger undesired immune reactions) and specific antibodies Fragments of the light and / or heavy chain variable region underlying antibody of the above type.
- specific antibodies Fragments of the light and / or heavy chain variable region underlying antibody of the above type The production resp. Obtaining such antibodies with given immunogens is the A person of ordinary skill in the art is familiar and need not be explained in more detail.
- the invention also relates to an isolated protein or peptide containing at least one of the sequences SEQ. ID 2 to 13, in particular one of the sequences SEQ. ID 14 to 17 or SEQ. ID 18 to 21, or one of the sequences Seq. ID 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or 39, in particular one of the sequences Seq. ID 27, 28, 29, 30, 32, 36, 37, or 38, or one of the sequences Seq. ID 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60, in particular one of the sequences Seq.
- An inventive antibody or. a protein or peptide according to the invention is preferably soluble in water, in particular in physiological saline solution, i. e. not artificially networked. Furthermore, an antibody according to the invention is superagonistic, i. e. stimulates the physiological action of the T-cell inhibitory receptor CTLA-4.
- the invention further relates to a pharmaceutical composition containing a monoclonal antibody according to the invention and / or an inventive Protein or peptide, and optionally at least one physiologically acceptable carrier and / or excipient, which will be explained in detail later. It is obtainable by mixing these components, the active ingredient being used in a physiologically effective dose. This dose can be easily determined in in-vitro experiments with cells and in animal experiments in the usual way.
- Such a pharmaceutical composition is for the prophylaxis and / or therapy of a disease or condition selected from the group consisting of "rheumatoid arthritis, type I diabetes, multiple sclerosis, systemic lupus erythematosus, psoriasis, ulcerative colitis, Crohn's disease, allergies, rejection of allograft organ transplant , in particular organ transplants of the following organs: heart, kidney, liver, pancreas, lung, bone marrow, and "graft-versus-host" disease suitable.
- the invention also includes a method for the prophylaxis and / or treatment of a above disease or condition wherein a patient is given the pharmaceutical composition in suitable dosage.
- Suitable counterions for ionic compounds are, for example, Na + , K + , Li + or cyclohexylammonium.
- Suitable solid or liquid galenic preparations are, for example, granules, powders, dragees, tablets, (micro) capsules, suppositories, syrups, juices, suspensions, emulsions, drops or solutions for injection (i.v., i.p., i .m., s.
- adjuvants such as carriers, blasting, binding, coating, swelling, lubricants or lubricants, flavoring agents, sweeteners and solubilizers, are used.
- adjuvants may be magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talcum,
- the invention further relates to a method for producing a monoclonal antibody according to the invention, wherein a nucleic acid according to the invention is introduced into a vector, wherein a cell is transfected by means of the vector, wherein the transfected cell is cultured, wherein a supernatant is separated from the cultured cells or the cultured cell is lysed and the lysate is recovered, and the monoclonal antibodies are separated from the separated supernatant or lysate.
- Example 1 Antibodies according to the invention
- Table 1 shows the binding properties of 4 new anti-CTLA-4 antibodies, 2 of which do not bind to the C "D loop of CTLA-4 (4.3F6B5 and 4.8H10H5) and 2 however, bind to it (3.7F10A2 and 4.7A8H6).
- the latter are reference antibodies and are not the subject of the present invention.
- the specificity of the antibodies to human CTLA-4 was investigated, both on transfected Jurkat E6.1 cells and on ex vivo activated human PBMCs (peripheral blood mononuclear cells). Cross-reactivity against rat CTLA-4 was demonstrated with a transfected BW cell line carrying the extracellular domain of rat CTLA-4 on the surface. Likewise, the cross-reactivity against the closely related T-
- Fig. 1 shows the most important examples
- CTLA-4 The specificity of antibodies to CTLA-4 was confirmed with human PBMCs previously stimulated ex vivo with PHA / IL-2. In resting cells, CTLA-4 is predominant localizes intracellularly and is brought to the surface only after activation. The thick curve shows the binding of the antibodies, the thin curve the binding of the isotype control to activated human PBMCs.
- C In view of a possible usability of the antibodies in
- Fig. Figure 2 shows the nonexistent specificity of 2 of 4 anti-CTLA-4 antibodies from Table 1 for the C "" D loop.
- the two antibodies according to the invention 4.3F6B5 and 4.8H10H5, which showed agonistic mode of action in functional assays (see Example 2), are not specific for the human C 'D loop.
- Jurkat E6.1 was used, which expresses a chimeric extracellular domain of CTLA-4 on the surface: this chimera consists of the murine receptor, in which the C S D loop against the corresponding human sequence, represented by the amino acids Pos 68 - 83, was exchanged.
- Fig. Figure 3 shows that binding of anti-CTLA-4 antibodies 4.8H10H5 and 4.3F6B5 to CTLA-4 by addition of recombinant CD80 can be competed.
- the Ergbenis suggests that 4.8H10H5 and 4.3F6B5 are located near the binding site for CD80, d. H . bind the MYPPPY loop, but not to the C 'D loop.
- the aim of this experiment was to further narrow the binding properties of the antibodies.
- Jurkat E6.1 cells carrying the extracellular domain on their surface were incubated with increasing concentration of CD80Fc protein and 1 ⁇ g / ml of CTLA-4 specific antibody. The co-incubation of recombinant protein and antibody leads to a
- Figure 10 shows the binding of the humanized antibodies to the extracellular domain of human CTLA-4. Shown is the binding of the humanized antibodies to transfected cells (thick curve) compared to binding of the isotype control (thin curve) to the same cells. The FACS analysis shows that in the course of humanization the specificity of the antibodies to human CTLA-4 is maintained.
- Antibodies 4.8H10H5 and 4.3F6B5 again, divided into heavy and light chains, with the border between the variable regions and the constant regions labeled.
- the sequences were determined by RT-PCR or. determined by protein sequencing (Edman degradation).
- Table 3 shows heavy chain sequences of the antibody TGN2122.
- H Table 4 shows the for the heavy chain coding nucleic acid.
- Table 5 shows heavy chain sequences of the antibody TGN2422.
- H Table 6 shows the heavy chain coding nucleic acid.
- Table 7 shows light chain sequences for both antibodies TGN2122. H and TGN2422.
- H Table 8 shows the light chain encoding nucleic acid.
- Table 9 shows heavy chain sequences of the antibody TGN2122.
- C. shows the heavy chain coding nucleic acid.
- Table 11 shows heavy chain sequences of the antibody TGN2422.
- C. shows the heavy chain coding nucleic acid.
- Table 13 shows light chain sequences for both antibodies TGN2122.
- C. Table 14 shows the light chain encoding nucleic acid.
- sequences Seq. IDs 31, 39, 52, and 60 are leader peptides that are not included in the current mature chains. Therefore, those antibodies are preferred which do not contain these sequences.
- TGN2122. C isotype IgG1
- TGN2422 was purified from mouse antibody 4.3F6B5
- Example 2 Effect of Antibodies According to the Invention on a Comparative Antibody Attached to C 'D Loop binds, as well as commercially available anti-CTLA-4 antibodies.
- FIG. Figure 4 shows the inhibitory effect of anti-CTLA-4 antibody 4.8H10H5 on the proliferation of human PBMCs.
- the aim of this proliferation inhibition assay was to identify a functionally novel antibody compared to previously known CTLA-4 specific antibodies.
- a superagonistic antibody As an essential property of a superagonistic antibody has been defined the ability to reduce the proliferation of human PBMC. Another criterion was that this effect with soluble, not artificially networked! Antibody is observed. These antibodies were evaluated as positive, reducing anti-CD3 (or superagonistic anti-CD28, not shown) T cell proliferation by at least 25%. Readout system was the measurement of proliferation by means of 3 H thymidine incorporation. In this assay system, the CTLA-4 specific antibodies were given in time with the activating anti-CD3 antibody and the proliferation determined after 63-66 hours.
- Antibody 4.8H10H5 was able to inhibit proliferation of T cells based on the above criteria. For comparison, an antibody not positively evaluated in this assay system (2.10B11A1) is listed. Shown is the relative proliferation in relation to the positive control (anti-CD3 induced proliferation). Further controls included the respective isotype control (IgGl or IgG2) and a commercially available antibody (BNI3, BD Pharmingen). The control commercial antibodies (14D3, 8H5, 3H1833, BNI3) with specificity for CTLA-4 had no effect. Fig.
- FIG. 5 shows the stimulatory effect of the anti-CTLA-4 antibodies 4.8H10H5 and 4.3F6B5 on the IL-2 production of Jurkat E6.1 cells expressing a chimeric CTLA-4 / CD28 molecule.
- Jurkat E6.1 cells expressing a chimeric CTLA-4 / CD28 receptor on their surface were used for this cell-autonomous read-out system for the functional characterization of the CTLA-4-specific MAK (D).
- D This consists of the extracellular domain of the CTLA-4 receptor and the transmembrane and intracellular domain of CD28.
- Activation of the chimeric receptor by CTLA-4-specific MAK induces CD28-specific activation markers such as IL-2 or CD69, which are detected by means of ELISA or ELISA. FACS analysis can be measured.
- Potentially superagonistic CTLA-4 specific antibodies can be identified in this system using CD28 specific
- Activation markers are identified. Control antibodies and CTLA-4 specific antibodies were cross-linked (using sheep anti mouse Ig) and incubated with 1 * 10 5 transfected Jurkat E6.1 cells for 48h. As an activation marker, IL-2 production was measured by ELISA.
- CTLA-4 specific antibodies (1 ⁇ g / ml) on the IL-2 production of transfected Jurkat cells expressing a chimeric CTLA-4 / CD28 receptor.
- B Effect of commercially available CTLA-4 specific antibodies (1 ⁇ g / ml) on the IL-2 production of transfected Jurkat cells expressing a chimeric CTLA-4 / CD28 receptor.
- C Effect of CTLA-4 specific antibodies (l ⁇ g / ml) on IL-2 production of untransfected Jurkat E6.1 cells lacking the chimeric receptor (representative experiments). Two of the antibodies tested (4.3F6B5, 4.8H10H5) induce the IL-2 production of transfected Jurkat cells by activation of the chimeric receptor, while none of the commercially available antibodies with specificity for CTLA-4 was able to do so.
- Fig. Figure 6 shows the stimulatory effect of the anti-CTLA-4 antibodies 4.8H10H5 and 4.3F6B5 on the CD69 induction of Jurkat E6.1 cells expressing a chimeric CTLA-4 / CD28 molecule.
- D Using the method shown in Fig. In addition to IL-2 production, the assay of CD69 expression as a further activation marker was measured by FACS analysis. In contrast to IL-2 production, CD69 is an early activation marker and can be detected after 4 h of incubation of the antibodies with the transfected cells.
- A Effect of CTLA-4-specific antibodies (1 ⁇ g / ml) on transfected CD69 expression Jurkat cells expressing a chimeric CTLA-4 / CD28 receptor
- B Effect of commercially available CTLA-4 specific antibodies (1 ⁇ g / ml) on the CD69 expression of transfected Jurkat cells carrying a chimeric CTLA-4 / CD28 receptor
- C Effect of CTLA-4 specific antibodies (l ⁇ g / ml) on CD69 expression of untransfected Jurkat E ⁇ .l cells lacking the chimeric receptor (representative experiments) As shown for IL-2, as well Antibodies 4.3F6B5 and 4.8H10H5 are able to activate the chimeric receptor, a
- FIG. Figure 7 shows that the stimulatory effect of the anti-CTLA-4 antibodies 4.8H10H5 and 4.3F6B5 on the chimeric CTLA-4 / CD28 construct by CD80 Fc protein can be reduced.
- Jurkat E. ⁇ . 1 cells expressing the chimeric CTLA-4 / CD28 receptor (see Fig. 5, 6) were incubated with increasing concentration of antibody and in each case 1 ⁇ g / ml CD80 Fc protein.
- Antibody-mediated CD69 expression is then reduced by CD80Fc as the recombinant protein is excessively incubated compared to the antibody. Rectangular squares show the current CD69 induction without CD80 co-incubation, the triangular curves show the CD69 induction diminished by I ⁇ g / ml CD80 Fc
- Antibodies In addition, the concentration-dependent binding of the antibodies and the Jurkat cells is shown.
- FIG. Figure 8 shows the cross-reactivity of the anti-CTLA-4 antibodies 4.8H10H5 and 4.3F6B5 with the rat CTLA-4 molecule and the stimulatory functionality of the antibodies in a chimeric receptor assay.
- A Binding of anti-CTLA-4 antibodies to rat CTLA-4 was demonstrated by BW cells expressing the extracellular domain of the rat receptor on its surface. Analogous to the chimeric receptor on Jurkat cells ( Figure 5), these cells express a chimeric CTLA-4 CD28 receptor consisting of rat CTLA-4 (extracellular domain) and mouse CD28 (transmembrane / intracellular domain) (bright line: anti-CTLA). 4 Akö, dark curve: isotype control).
- FIG. Figure 9 shows the inhibitory in vivo effect of anti-CTLA-4 antibodies 4.8H10H5 and 4.3F6B5 on CD28
- lymph nodes and spleens were obtained and analyzed by FACS for the activation marker CD25.
- a total of three experiments with varying antibody concentrations were performed.
- Both tested CTLA-4 specific antibodies reduced the JJ316-induced CD25 expression on lymph node as well as on spleen cells in 3 independent experiments by approx. 30 - 40%. Shown is a representative result.
- Antibodies of the invention from both IgG1 and IgG4 isotypes, effectively induce CD69 surface expression while the isotype control resp. the addition of cell culture medium without effect remained (representative result).
- FIG. 12 shows the inhibitory effect of the antibody TGN2122.
- a recall-response-assay 10 ⁇ 5 human PBMCs of healthy donors with 2, 5 ⁇ g / ml tetanus toxoid were activated and at the same time the corresponding CTLA-4 specific antibodies resp.
- the isotype control given to the experimental approach.
- the proliferation was measured by 3 H thymidine incorporation after 120 h incubation.
- 3 H-thymidine was added to the experimental batch for the last 15-18 h of the test duration and the 3 H-Thymidineinbau determined.
- the corresponding isotype control and an approach in which unactivated non-antibody cells were included were included. Both antibodies were able to effectively inhibit tetanus toxoid-induced proliferation. In contrast, the isotype control showed no such inhibition.
- the superagonistic properties of antibodies according to the invention are shown since inhibition in soluble form, i. e. without artificial cross-linking, took place.
- n is specified in sequences X, the specified n can vary by + 1.
- MGWSCIILFLVATATGVHS Leader peptide, not part of mature HC
- H HC nucleotide sequence (SEQ ID NO: 40)
- MGWSCIILFLVAT ⁇ TGVHS Leader peptide, not part of the mature HC
- MGWSCIILFLVAT ⁇ TGVHS Leader peptide, not part of the mature LC
- MGWSCIILFLVATATGVHS Leader peptide, not part of mature HC
- MGWSCIILFLVATATGVHS Leader peptide, not part of mature HC
- MGWSCIILFLVATATGVHS Leader peptide, not part of the mature LC
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004063494A DE102004063494A1 (en) | 2004-12-23 | 2004-12-23 | antibody |
PCT/DE2005/002328 WO2006066568A2 (en) | 2004-12-23 | 2005-12-22 | Antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2111415A2 true EP2111415A2 (en) | 2009-10-28 |
Family
ID=36337542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05826461A Withdrawn EP2111415A2 (en) | 2004-12-23 | 2005-12-22 | Monoclonal agonistic anti-ctla-4 antibodies |
Country Status (4)
Country | Link |
---|---|
US (1) | US20090123477A1 (en) |
EP (1) | EP2111415A2 (en) |
DE (1) | DE102004063494A1 (en) |
WO (1) | WO2006066568A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100135257A (en) * | 2008-03-13 | 2010-12-24 | 바이오테스트 아게 | Agent for treating disease |
CA2718191C (en) * | 2008-03-13 | 2018-05-15 | Biotest Ag | Agent for treating disease |
BRPI0909179A2 (en) * | 2008-03-13 | 2015-08-25 | Biotest Ag | Pharmaceutical composition and method of treatment of an autoimmune disease. |
CA2738598C (en) * | 2008-09-29 | 2017-11-21 | Biotest Ag | Composition for treating disease |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
US9216189B2 (en) | 2010-01-25 | 2015-12-22 | Icahn School Of Medicine At Mount Sinai | Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers |
SG11201609721WA (en) | 2014-05-28 | 2016-12-29 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
CN105296433B (en) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | A kind of CTLA4 antibody, its medical composition and its use |
MA53355A (en) | 2015-05-29 | 2022-03-16 | Agenus Inc | ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF |
CN114605548A (en) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | anti-PD-1 antibodies and methods of use thereof |
IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods of use thereof |
KR102424513B1 (en) | 2015-12-14 | 2022-07-25 | 마크로제닉스, 인크. | Bispecific molecules with immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
EP3471753A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
AU2017343621B2 (en) | 2016-10-11 | 2021-12-02 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
PT3551660T (en) | 2016-12-07 | 2023-11-30 | Ludwig Inst For Cancer Res Ltd | Anti-ctla-4 antibodies and methods of use thereof |
GB201711785D0 (en) * | 2017-07-21 | 2017-09-06 | Berlin-Chemie Ag | Antibodies |
CN111511762A (en) | 2017-08-21 | 2020-08-07 | 天演药业公司 | anti-CD137 molecules and uses thereof |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
AU2019287765A1 (en) | 2018-06-15 | 2021-01-07 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
JP2023509359A (en) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | Combination anticancer therapy with inducers of iron-dependent cell degradation |
EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
KR20230165276A (en) | 2021-03-31 | 2023-12-05 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | Thanotransmission polypeptides and their use in the treatment of cancer |
AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023007023A1 (en) | 2021-07-30 | 2023-02-02 | Affimed Gmbh | Duplexbodies |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006526414A (en) * | 2003-06-02 | 2006-11-24 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Deimmunized anti-CD3 antibody |
-
2004
- 2004-12-23 DE DE102004063494A patent/DE102004063494A1/en not_active Ceased
-
2005
- 2005-12-22 EP EP05826461A patent/EP2111415A2/en not_active Withdrawn
- 2005-12-22 WO PCT/DE2005/002328 patent/WO2006066568A2/en active Application Filing
- 2005-12-23 US US11/318,352 patent/US20090123477A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2006066568A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2006066568A2 (en) | 2006-06-29 |
WO2006066568A3 (en) | 2006-08-31 |
US20090123477A1 (en) | 2009-05-14 |
DE102004063494A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006066568A2 (en) | Antibody | |
KR102340687B1 (en) | anti-LAG-3 antibody | |
KR101200188B1 (en) | Mutants of anti-cd40 antibody | |
KR101262032B1 (en) | ANTIBODIES TO MAdCAM | |
DK2519543T3 (en) | HETERODIMER BINDING PROTEINS AND USE THEREOF | |
AU2024200534A1 (en) | Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof | |
AU2024219825A1 (en) | Humanized anti-MUC1* antibodies | |
AU2024205484A1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
CN111465615A (en) | anti-CD137 molecules and uses thereof | |
KR20200006115A (en) | Treatment of Cancer with Anti-GITR Agonist Antibodies | |
WO2006028197A1 (en) | Anti-a33 antibody | |
KR20210093265A (en) | Fusion proteins and their uses | |
EP1341553A1 (en) | Silensed anti-cd28 antibodies and use thereof | |
AU2002226086A1 (en) | Silensed anti-CD28 antibodies and use thereof | |
US20220119521A1 (en) | Antibodies to MAdCAM | |
KR20220131279A (en) | Anti-LAG3 monoclonal antibody and its manufacturing method and application | |
RU2800923C2 (en) | Function protein and its use | |
AU2021264846A1 (en) | TGFβR2 extracellular domain truncated molecule, fusion protein of TGFβR2 extracellular domain truncated molecule and anti-EGFR antibody, and anti-tumor use of fusion protein | |
OA20299A (en) | Antibodies to MAdCAM. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAJ | Public notification under rule 129 epc |
Free format text: ORIGINAL CODE: 0009425 |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090731 |
|
18D | Application deemed to be withdrawn |
Effective date: 20070724 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THERAMAB LLC |
|
17Q | First examination report despatched |
Effective date: 20091211 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
R18D | Application deemed to be withdrawn (corrected) |
Effective date: 20120703 |